Wealth managers: How and why we use structured products

clock • 6 min read

Despite negative press, structured products still form part of many wealth manager portfolios. Joanna Faith looks into their appeal.

It has been five years since the collapse of Lehman Brothers brought to the fore the issue of counterparty risk in structured products. While some members of the intermediary community still regard the products as toxic, many continue to back them as good diversifying tools.       This has led to the volume of structured products issued increasing since 2007 and has coincided with a rise in the sophistication of products. Lisa Chaudhuri, UK investor solutions at Barclays, saw a significant rise in the use of structures across wealth management firms from 2007 to 2010, but admits that ove...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now


Already an Investment Week


More on Specialist

While thematic funds offer diversification and a specialist knowledge base, investors must also consider the sensitivity to real bond yields inherent in these funds.

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
Deal volumes fell last year as rising interest rates brought the end of cheap money

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Ali H. Munawar, CEO of Pledge Therapeutics

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read